Merck & Company Inc (MRK)vsSpero Therapeutics Inc (SPRO)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
SPRO
Spero Therapeutics Inc
$1.13
+0.89%
HEALTHCARE · Cap: $70.46M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 141545% more annual revenue ($66.57B vs $47.00M). SPRO leads profitability with a 15.7% profit margin vs 4.8%. SPRO trades at a lower P/E of 8.6x. SPRO earns a higher WallStSmart Score of 54/100 (C-).
MRK
Hold36
out of 100
Grade: F
SPRO
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for SPRO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 35 in profit
Earnings expanding 75.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Revenue declined 95.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SPRO
The strongest argument for SPRO centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 15.7% and operating margin at 14.1%.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SPRO
The primary concerns for SPRO are Market Cap, Revenue Growth, Free Cash Flow.
Key Dynamics to Monitor
MRK profiles as a value stock while SPRO is a declining play — different risk/reward profiles.
SPRO carries more volatility with a beta of 1.48 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
SPRO scores higher overall (54/100 vs 36/100), backed by strong 15.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Spero Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?